Clinical orthotopic cardiac transplantation.
The results of orthotopic cardiac transplantation have improved dramatically since the early experiences in the late 1960s. After almost 20 years of research and experience and the introduction of cyclosporine, 1 and 5 year survival rates are now 80 percent and 60 percent, respectively. The number of potential recipients far exceeds that of available donors, which is the limiting factor in cardiac transplantation. Complications related to immunosuppressive therapy remain significant, and despite decreased length of hospitalization, costs remain high. The majority of patients have good functional rehabilitation and are free of cardiac symptoms. Moreover, orthotopic cardiac transplantation has finally become a therapeutic treatment of end-stage heart disease.
Slater
A D
AD
Klein
J B
JB
Gray
L A
LA
D000367:Age Factors; D003524:Cyclosporins / Q000627:therapeutic use; D006084:Graft Rejection; D006680:HLA Antigens / Q000032:analysis; D006331:Heart Diseases / Q000601:surgery; D016027:Heart Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D008722:Methods; D011183:Postoperative Complications / Q000453:epidemiology; D012306:Risk; D014019:Tissue Donors; D009927:Tissue and Organ Procurement
D003524:Cyclosporins; D006680:HLA Antigens